Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024
– Oral Presentation of complete data from the three-year MATCH Phase 2 trial
– Poster Presentation demonstrating preclinical proof of concept of safety and efficacy of RTX001, an autologous engineered macrophage cell therapy for end stage liver disease
Edinburgh and London, UK, 1 October 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces two abstracts have been selected for presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. The conference will take place in San Diego, California, between 15-19 November 2024.
